The subscription period in IRLABS’s rights issue of shares commence today

Today, on 3 July 2025, the subscription period commences in IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) rights issue of shares of series A with preferential rights for existing shareholders up to approximately MSEK 136 (the “Rights Issue”), which was resolved and announced on 24 June 2025. The subscription period for the Rights Issue will run until and including 17 July 2025. However, please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier response deadline that may apply.

IRLAB publishes information document in connection with the rights issue

The Board of Directors of IRLAB has resolved on an 85 per cent secured rights issue of approximately SEK 136 million and receives extended debt financing of SEK 30 million